IgE glycosylation and impact on structure and function: A systematic review.

Autor: McCraw AJ; St. John's Institute of Dermatology, School of Basic & Medical Biosciences & KHP Centre for Translational Medicine, Guy's Hospital, King's College London, London, UK., Palhares LCGF; St. John's Institute of Dermatology, School of Basic & Medical Biosciences & KHP Centre for Translational Medicine, Guy's Hospital, King's College London, London, UK., Hendel JL; Department of Chemistry, Trent University, Peterborough, Ontario, Canada., Gardner RA; Ludger, Ltd., Abingdon, Oxfordshire, UK., Santaolalla A; Translational Oncology & Urology Research (TOUR), School of Cancer and Pharmaceutical Sciences, King's College, London, UK., Crescioli S; St. John's Institute of Dermatology, School of Basic & Medical Biosciences & KHP Centre for Translational Medicine, Guy's Hospital, King's College London, London, UK., McDonnell J; Randall Centre for Cell and Molecular Biophysics, School of Basic & Medical Biosciences, King's College London, London, UK., Van Hemelrijck M; Translational Oncology & Urology Research (TOUR), School of Cancer and Pharmaceutical Sciences, King's College, London, UK., Chenoweth A; St. John's Institute of Dermatology, School of Basic & Medical Biosciences & KHP Centre for Translational Medicine, Guy's Hospital, King's College London, London, UK.; Breast Cancer Now Research Unit, School of Cancer & Pharmaceutical Sciences, Guy's Cancer Centre, King's College London, London, UK., Spencer DIR; Ludger, Ltd., Abingdon, Oxfordshire, UK., Wagner GK; St. John's Institute of Dermatology, School of Basic & Medical Biosciences & KHP Centre for Translational Medicine, Guy's Hospital, King's College London, London, UK.; School of Pharmacy, Medical Biology Centre, Queen's University Belfast, Belfast, UK., Karagiannis SN; St. John's Institute of Dermatology, School of Basic & Medical Biosciences & KHP Centre for Translational Medicine, Guy's Hospital, King's College London, London, UK.; Breast Cancer Now Research Unit, School of Cancer & Pharmaceutical Sciences, Guy's Cancer Centre, King's College London, London, UK.

Publikováno v: Allergy [Allergy] 2024 Oct; Vol. 79 (10), pp. 2625-2661. Date of Electronic Publication: 2024 Aug 04.

Comparison of oral melphalan, CCNU, and BCNU with and without vincristine and prednisone in the treatment of multiple myeloma. Cancer and leukemia group B experience

Autor: M. Robert Cooper, Janet Cuttner, Thomas F. Pajak, Gibbons G. Cornwell, Sameer Rafla, O. Ross McIntyre, Robert A. Kyle, Linda P. Glowienka, Farid I. Haurani, Kurt Brunner, S. Kochwa, Richard T. Silver, Edward S. Henderson

Publikováno v: Cancer. 50:1669-1675

A total of 361 evaluable patients with previously untreated multiple myeloma were randomized to receive oral melphalan (0.15 mg/kg/day for seven days, followed by 0.05 mg/kg/day after recovery from the nadir of the leukocytes), BCNU (150 mg/m2 intrav

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6f9881252d0c408589ec649f16bd2afe
https://doi.org/10.1002/1097-0142(19821101)50:9<1669::aid-cncr2820500902>3.0.co

Pathogenesis of shigella diarrhea. Serum anticytotoxin antibody response produced by toxigenic and nontoxigenic Shigella dysenteriae 1

Autor: Richard B. Hornick, Gerald T. Keusch, Myron M. Levine, Mary Jacewicz, S Kochwa

Publikováno v: Journal of Clinical Investigation. 57:194-202

The serum antitoxin response to the cytotoxin contained in preparations of Shigella dysenteriae 1 (Shiga's bacillus) exotoxin was studied in natural and experimental infections of man. Natural infection resulted in the rapid appearance of toxin-neutr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac673729896f40b0ace623366dd890b8
https://doi.org/10.1172/jci108259

Response to therapy in IgG myeloma patients excreting lambda or kappa light chains: CALGB experience

Autor: Thomas F. Pajak, S. Kochwa, McIntyre Or, Cornelius J. Cornell, BB Weksler

Publikováno v: Blood. 54:23-29

Sixty-eight previously untreated patients with IgG myeloma who were entered into five protocols of Cancer and Leukemia Group B (CALGB) were studied in order to determine the possible influence of excretion of kappa versus lambda urinary light chains

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::131c01f9e0f231c055f3b55d58e04fb6
https://doi.org/10.1182/blood.v54.1.23.bloodjournal54123

Vincristine and prednisone prolong the survival of patients receiving intravenous or oral melphalan for multiple myeloma: Cancer and Leukemia Group B experience

Autor: Sameer Rafla, Morton Coleman, Edward S. Henderson, Thomas F. Pajak, K Brunner, S. Kochwa, L P Glowienka, O R McIntyre, Cooper Mr, G G Cornwell rd

Publikováno v: Journal of Clinical Oncology. 6:1481-1490

A total of 589 patients with previously untreated multiple myeloma were randomized to receive daily oral melphalan, pulse-dose intravenous (IV) melphalan, carmustine (BCNU), or lomustine (CCNU). All patients received an initial tapering course of pre

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7063f796c47ff7f3c87fc4fbcfa08332
https://doi.org/10.1200/jco.1988.6.9.1481